anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Hospital-acquired infections are a common complication for patients with moderate or severe traumatic brain injury (TBI), contributing to morbidity and mortality. As infection-mediated immune responses can predispose towards epilepsy, we hypothesized that post-injury hospital-acquired infections increase the risk of post-traumatic epilepsy (PTE).
METHODS: A retrospective cohort study of adults with moderate to severe TBI was conducted using data from the Victorian State Trauma Registry in Australia. Infections were identified from the International Statistical Classification of Diseases and Related Health Problems 10th Revision-Australian Modification (ICD-10-AM) codes, and diagnosis of PTE was determined by the Glasgow Outcome Scale - Extended questionnaire regarding epileptic fits at 24 months follow-up.
RESULTS: Of all TBI patients (n = 15 152), 24% had evidence of having had any type of infection, with the most common being pneumonia, urinary tract, and respiratory infections. Of those who responded to the PTE question at 24 months (n = 1361), 11% had developed PTE. Univariable analysis found that the incidence of PTE was higher in patients who had any type of infection compared to patients without an infection (p < 0.001). After adjustment for covariates associated with both development of PTE and risk of infection, multivariable analysis found a solid association between infection and PTE (adjusted RR = 1.59; 95% CI: 1.11-2.28; p = 0.011). Having any type of complicating infection acquired during admission was also associated with poor GOSE outcomes at subsequent follow-ups (adjusted OR = 0.20; 95% CI: 0.11-0.35, p < 0.001).
SIGNIFICANCE: These findings suggest that hospital-acquired infections contribute to PTE development after TBI. Future investigation into infections as a modifiable target to reduce poor outcomes after TBI is warranted.
PLAIN LANGUAGE SUMMARY: Hospital-acquired infections are common in patients with traumatic brain injuries. A database study of adults with moderate or severe brain injuries in Australia examined whether these infections are associated with the development of epilepsy after a brain injury. 24% of patients had infections, with pneumonia and urinary tract infections being the most common. Of those surveyed 2 years after the injury, 11% developed post-traumatic epilepsy. Patients with infections had a significantly higher risk of epilepsy, even when accounting for other known risk factors, and infections were also linked to poor outcomes more broadly. The study suggests that preventing hospital-acquired infections could be a crucial target for improving outcomes after traumatic brain injuries.
The study will be conducted at no less than 5 clinical centers. Patients with peripheral pulmonary nodules suspicious for malignancy will be enrolled in the study. ENB will be performed with/without other guided bronchoscopy techniques and/or ROSE. Different biopsy methods will be recorded as well. The primary endpoint is the diagnostic yield of ENB. The secondary endpoints include factors affecting diagnostic yield, operation time, complications, safety and so on.
Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
Conceptual replications are part and parcel of education science. Methodologically rigorous conceptual replication studies permit researchers to test and strengthen the generalizability of a study's initial findings. The current conceptual replication sought to replicate the efficacy of a small-group, first-grade mathematics intervention with 240 first-grade students with mathematics difficulties in a new geographical region. Participating students were randomized into one of three conditions: (a) 2:1 mathematics intervention group, (b) 5:1 mathematics intervention group, or (c) business-as-usual instruction. Relative to the original study, findings from the replication varied. When comparing the treatment groups to the control, results suggested positive effects on all outcome measures, including a follow-up assessment administered one year later. However, differences between the two treatment groups based on group size were not found in the mathematics outcome measures. Both groups also received commensurate levels of observed instructional interactions. Implications for unpacking contextual differences between original research and their replications as well as using future research to explore the quantity and quality of instructional interactions as ways to explain variation in findings of group size are discussed.
The present invention relates generally to a novel human T-cell lymphotropic, or leukemia, virus type II (HTLV-II) isolate designated NRA. HTLV-II NRA  was originally isolated from a patient with atypical hairy cell leukemia. Preliminary restriction analysis of this isolate demonstrated that it differs genetically from the prototypical HTLV-II isolate Mo. HTLV-II NRA  proviral molecular clones were obtained and the entire nucleotide sequence of the virus ascertained. The claimed invention is particularly directed toward the gp46 and p21 e  envelope proteins encoded by the env gene. Methods and kits for the detection of HTLV-II antibodies employing these envelope proteins are also described.
PURPOSE:To provide prepared powder for improving the dispersibility of vitamin E, and composed of vitamin E, gum, dextrin, and a mono- or disaccharide. CONSTITUTION:The objective powder containing vitamin E is prepared by using vitamin E, a gum (e.g. gum arabic, xanthan gum, traganth gum, guar gum, tamarind seed polysaccharide, etc.), dextrin and a monosaccharide (e.g. glucose, fructose, galactose, xylose, etc.) or a disaccharide (e.g. sucrose, lactose, maltose, maltitol, etc.) as essential components. The amount of the mono- or disaccharide is 1-15% of the whole composition. If the amount is below the lower limit, the dispersibility is insufficient, and if it exceeds the upper limit, the powder becomes highly hygroscopic and its storage stability becomes poor.
FIELD: medicine, neurology. SUBSTANCE: the present innovation deals with treating Parkinson disease, atherosclerotic encephalopathy accompanied by disorders of intellect and memory, functional pain syndromes of face and mouth cavity. The method deals with carrying out electroimpact upon cerebral tissue daily for 10 d at preliminary body premedication due to intravenous injection of metacin at 0.5- 1.0 ml quantity and short-term mononarcosis as dithilin at 0.3-0.5 mg/kg patient's body weight and artificial pulmonary ventilation. Moreover, electroimpact should be conducted due to either bilateral or monopolar application of electrodes onto patient's head at 850 mA current power at 27-40 Hz frequency for 0.1- 1.0 sec at sparing set of impulses amplitude followed by control inspection for the patient. Moreover, before each seance of electroimpact one should perform medicinal stimulation of these neurotransmitters. EFFECT: optimal complex therapy in patients. 1 cl
Voriconazole clearance in children (2-12 years old) is 3-fold higher and bioavailability is one half of adult values. An important gap in knowledge exists that explain the mechanisms that result in higher clearance and lower bioavailability of voriconazole and places children at a substantial risk for sub-therapeutic concentrations and treatment failures. Preliminary data suggests that intestinal first-pass metabolism is responsible for the lower bioavailability in children, but not in adults. By inhibiting intestinal metabolism with grapefruit juice, the extent of the effect of intestinal first-pass metabolism on voriconazole pharmacokinetics can be determined. Inpatient children at the Children's Hospital of Philadelphia who are receiving oral voriconazole as standard of care will be enrolled in an open label, cross-over clinical trial to monitor plasma voriconazole levels after voriconazole administration with and without grapefruit juice to inhibit intestinal metabolism of voriconazole. The proposed research will elucidate the role of intestinal metabolism in the reduced oral bioavailability of voriconazole in children, which can be incorporated into a model simulation to guide accurate dosing.
Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
Prior studies have shown that this Chinese herbal formulation is safe and well-tolerated in food allergic individuals. While oral immunotherapy (OIT) can lead to desensitization, it remains uncertain whether this treatment can lead to lasting protection. Therefore, this study aims to use the Chinese herbal formula in combination with OIT to determine whether sustained protection can be achieved. All subjects will receive multi-allergen OIT, along with a 4 month course of omalizumab to provide added safety for the initial dose escalation and build up phases. Subjects will be randomized to receive active Chinese herbal formula or placebo. Subjects will be treated with OIT for 2 years and then food challenges will be performed to assess for desensitization. For those who achieve desensitization, all treatments will be discontinued and food challenges will be performed 3 months later to assess for sustained unresponsiveness.
Patients who consent to participate in the study will come to the clinic one week prior to the scheduled date of hospitalization in the Epilepsy Monitoring Unit (EMU). At this visit a complete physical examination including vital signs and complete neurological examination, mental status, cranial nerves, motor examination, deep tendon reflexes, sensory examination, coordinator and gait will be performed. Baseline laboratory studies including complete blood count, serum electrolytes, renal and liver function studies and serum pregnancy test for female patients will also be performed. Study medication will be dispensed at this visit.

Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge. A follow-up clinic visit for the patient will be scheduled 1 month following hospital discharge, as is the usual protocol for patients undergoing VET at our institution.
The invention relates to producing biologically active chitosan products and the derivatives thereof and can be used for producing cosmetic, health and beauty, and pharmacological preparations, biologically active additives for food and food products, in particular creams, ointments, gels, oils, emulsions, suspensions, powders, tablets and films. The aim of said invention is to develop a chitosan product exhibiting a high transdermal permeability characteristic. The aim is achieved by producing a chitosan product which has pH-neutral reaction and consists of chitosan particles having a flexible structure. Said chitosan product is embodied in the form of lamellar nanocapsules which are provided with a chitosan envelope and whose size is less than 100 nm. The maximum of a distribution function according to the sizes of the nanocapsules ranges from 0.1 to 500 nm. Said aim is also achieved by the inventive method for producing said chitosan product, the derivatives thereof in the form of gels and emulsions, and the biologically active composition which are based thereon.
The invention relates to a faked guaiane sesquiterpene lactone compound-Morgan blowball lactone A and the medicinable salt. The chemical name is 1-ketone-11(R)-hydroxyl-3, 5, 1(10)-trienin-faked lignum benedictum-8 alpha, 12-lactone. The compound could make medicine vehicle or medicine medicinal preparation with medicinable salt. The medicine contains other antibacterial druy. The preparation includes tablet, granule, capsule, oral liquid, drop pills, injection, skin penetrating agent, aerosol, etc. the compound could be used in medicine to prevent and cure anti gram positive fungus.
Efficacy of a single intravenous dose of palonosetron hydrochloride injection in preventing acute and delayed nausea and vomiting associated with MEC or HEC were studied in 4 trials. In these double-blind studies, complete response rates (no emetic episodes and no rescue medication) and other efficacy parameters were assessed through at least 120 hours after administration of chemotherapy. The safety and efficacy of palonosetron hydrochloride injection in repeated courses of chemotherapy was also assessed. 

Moderately Emetogenic Chemotherapy

Two double-blind trials (Study 1 and Study 2) involving 1132 patients compared a single dose of palonosetron hydrochloride injection with either a single-dose of ondansetron (Study 1) or dolasetron (Study 2) given 30 minutes prior to MEC, including carboplatin, cisplatin less than or equal to 50 mg/m², cyclophosphamide less than 1500 mg/m², doxorubicin greater than 25 mg/m², epirubicin, irinotecan, and methotrexate greater than 250 mg/m². Concomitant corticosteroids were not administered prophylactically in Study 1 and were only used by 4 to 6% of patients in Study 2. The majority of patients in these studies were women (77%), White (65%) and naïve to previous chemotherapy (54%). The mean age was 55 years. 

Highly Emetogenic Chemotherapy

A double-blind, dose-ranging trial evaluated the efficacy of a single intravenous dose of palonosetron hydrochloride injection from 0.3 to 90 mcg/kg (equivalent to less than 0.1 mg to 6 mg fixed dose) in 161 chemotherapy-naïve adult cancer patients receiving HEC, either cisplatin greater than or equal to 70 mg/m² or cyclophosphamide greater than 1100 mg/m². Concomitant corticosteroids were not administered prophylactically. Analysis of data from this trial indicates that 0.25 mg is the lowest effective dose in preventing acute nausea and vomiting associated with HEC. 

A double-blind trial involving 667 patients compared a single intravenous dose of palonosetron hydrochloride injection with a single intravenous dose of ondansetron (Study 3) given 30 minutes prior to HEC, including cisplatin greater than or equal to 60 mg/m², cyclophosphamide greater than 1500 mg/m², and dacarbazine. Corticosteroids were co-administered prophylactically before chemotherapy in 67% of patients. Of the 667 patients, 51% were women, 60% White, and 59% naïve to previous chemotherapy. The mean age was 52 years. 

Efficacy Results

Studies 1, 2 and 3 show that palonosetron hydrochloride injection was effective in the prevention of nausea and vomiting associated with initial and repeat courses of MEC and HEC in the acute phase (0 to 24 hours) [Table 5]. Clinical superiority over other 5-HT3 receptor antagonists has not been adequately demonstrated in the acute phase. In Study 3, efficacy was greater when prophylactic corticosteroids were administered concomitantly. 

Studies 1 and 2 show that palonosetron hydrochloride injection was effective in the prevention of nausea and vomiting associated with initial and repeat course of MEC in the delayed phase (24 to 120 hours) [Table 6] and overall phase (0 to 120 hours) [Table 7].
Preparation of a compound of formula: <IMAGE> by reaction of a 1-R-7-RO-2-tetralone with a 1,4-dihalo-2-butene compound, to obtain the corresponding 1,1'-R-halobutenyl substituted tetralone. This compound is then cyclised to produce, by closing of the butanyl ring in position 3, the corresponding tricyclic ketone. By reaction with an amine derivative H2N-Y, the ketone group is converted to an imino group which is then reduced to an NH2 group. The group OR can be converted to an OH group and the NH2 group can be converted to a secondary or tertiary amino group. A mixture of optical isomers can be separated and acid addition salts can be prepared. These compounds are useful as analgesic agents and as intermediates for the preparation of other analgesic agents.
Participants receive an organic grass-fed steak meal in the morning. After a washout period of at least 7 days, they then receive the alternative meal, conventional-fed steak meal in the morning.
The present invention relates to a Chinese medicine preparation for treating insomnia, which is prepared from 1 to 5 portions of schisandra, 1 to 4 portions of loquat leaves, 1 to 4 portions of pilose asiabell root, 1 to 3 portions of prepared fleece flower root and 1 to 3 portions of astragalus root as raw materials according to portions by weight. The Chinese medicine preparation adopts the pilose asiabell root, the astragalus root and the schisandra for invigorating hearts and spleens and nourishing blood for tranquillization, adopts the prepared fleece flower root for supplementing essence and blood and adopts the loquat leaves for dredging phlegm and heat. The present invention has the advantages of precise recipe and strict compatibility. Schisandra tranquillization mixture agent as a hospital preparation has the efficiency of strengthening spleens and replenishing qi and relieving mental stress. The present invention is mainly used for treating copos, neurasthenia and insomnia in clinics. Through clinical application for many years, the present invention has the advantages of definite therapeutic effect and non toxic side effect.
The present invention is a method to produce novel composites based on microcapsules or microspheres embedded in contiuous polymeric matrices. Both non-bioerodible and erodible polymers can be used. Material can be incorporated into the microcapsules or microspheres for subsequent release. In one embodiment of the present invention, spheres are homogeneously dispersed in a polymer matrix and then forced to release their contents by exposure to temperature, light or ultrasound. Alternatively, polymers which degrade as a function of time or hydrolysis can be used for controlled releases. The polymer composites have completely different properties from either a continuous polymer matrix or microcapsules or microspheres and are therefore useful for a wide variety of applications. When carbon tetrachloride is the incorporated material, the film is useful as a flame retarding device. When foaming agents are used, especially UV or heat sensitive materials, gas can be evolved inside each capsul 
     The Government has rights in this invention pursuant to Grant Number 5-R01-GM26698 awarded by the Department of Health and Human Services.
The recovery of motor function is a primary goal for individuals diagnosed with neurological disease, such as Stroke, Parkinson's Disease, Multiple Sclerosis. Various rehabilitation methods have been using in neurorehabilitation hospital, including conventional training and those involving technological devices. Nowadays, the integration of technology into rehabilitation room has been expanding within the National Health System, and their effectiveness in enhancing functionality and quality of life remains a subject of ongoing research in rehabilitation. In addition to rehabilitation devices, such as robotic and virtual reality systems, home automation system may play a crucial role in monitoring and recording patient movements. These sensors can also be employed for home automation in environments such as hospital rehabilitation settings, helping to reduce paid carer hours, quantify the impact of automated data acquisition on the functionality and offer many benefits to people with a disability. Indeed, potentially, the application of home automation system in technological rehabilitation rooms, may allow for the synchronization of environmental data with the patient's clinical history, facilitating the study of functional recovery.

This study is a part of the HosmartAI project (EU Horizon 2020 research and innovation program - grant agreement No 101016834 Pilot #3). The main aim of HoSmartAI project is to develop hospitals based on artificial intelligence (AI) technologies. In Pilot #3, the investigators will integrate data collected by technological devices for motor rehabilitation and home automation sensors installed in room (HosmartAI room) at the Neuromotor Rehabilitation Service of the San Camillo IRCCS Hospital (Venice, Italy). These sensors are able to detect the effective numbers of minutes of therapy, the number of sessions delivered in the room, and detect the presence and falls of the patients. Moreover, all these sensors are managed directly by physiotherapists through an App for smartphone. All data collected will be integrated in a cloud infrastructure, where physiotherapist will check the patients' profile and data collected from clinical assessment and home automation sensors.

In the study, the investigators will enroll patients with neurological disease and motor impairment who are hospitalized in Camillo IRCCS Hospital (Venice, Italy). The treatment (5time/week, for 3 weeks) will consist of 1 hour/day of motor training provided by technological devices (i.e., OAK, VRRS, AMADEO, PABLO) in the HoSmartAI room, in addition to daily 1 hour of conventional motor training. Firstly, the patients will be assessed to define their motor function and personalize the treatment based on their needs, to improve balance, manual dexterity, or upper and lower limb motor recovery. Then, at the end of the treatment, the patients will be assessed using validated clinical scales and questionnaire to determine the clinical effect and patient-reported outcome measurements (i.e., usability, technology acceptability, and user satisfaction).